A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2027

Conditions
Overall Response Rate
Interventions
DRUG

Combination of Cardonizumab with Lenvatinib and SOX regimen

"Phase 1: Conduct a ramp up test on the dosage of lenvatinib according to the traditional 3+3 design; Phase 2: 6 cycles of treatment with candenizumab+lenvatinib+SOX regimen (Q3W); For patients who have not progressed, they will enter the third stage of maintenance treatment.~Phase 3: Maintenance therapy with candenizumab, lenvatinib, and tigio (Q3W)."

Trial Locations (1)

Unknown

RECRUITING

Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Medical University

OTHER